|
|
||||||||
Departments of Radiology and Psychiatry, The Mount Sinai Medical Center and Bronx VA Medical Center, New York, New York
Correspondence: For correspondence or reprints contact: Shankar Vallabhajosula, PhD, Associate Professor of Radiology, Division of Nuclear Medicine, Mount Sinai Medical Center, New York, NY 10029.
ABSTRACT
Studies have suggested that antipsychotic drug therapy with haloperidol in schizophrenic patients requires an optimal dose that blocks the brain dopamine D2 receptors. We evaluated the effect of different doses of haloperidol on D2 receptor occupancy in schizophrenia. Methods: Three normal subjects and three patients with acute schizophrenia had serial brain SPECT imaging studies (every 5 min) for 3 hr following the injection of [123I] IBZM. The patients had IBZM studies off medication and at different doses (110 mg) of haloperidol. Results: The basal ganglia (BG) were well visualized in normals and in schizophrenics off medication. After haloperidol therapy, SPECT images showed qualitatively diminished activity in the basal ganglia. ROIs were drawn over the basal ganglia and cerebellum (CE). The results were expressed as BG/CE ratios. At 2 hr postinjection of IBZM, the mean BG/CE ratio in normals was 1.75 ± 0.025. In schizophrenics, the BG/CE ratio off medication was 1.54 ± 0.12. The BG/CE ratio showed an inverse relationship to haloperidol dose; 1.46 at 1 mg, 1.25 at 4 mg and 1.05 at 10 mg, respectively. Conclusion: These results demonstrate that IBZM brain SPECT imaging studies are potentially useful to relate the antipsythotic drug D2 receptor occupancy with the administered dose in schizophrenic patients and may ultimately help optimize antipsychotic treatment.
Key Words: iodine-123-IBZM receptor imaging schizophrenia
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | THE JOURNAL OF NUCLEAR MEDICINE |